文献速递心境障碍

重复经颅磁刺激治疗美国退伍军人难治性重性抑郁的随机临床试验

Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

该双盲假对照随机临床试验纳入164名难治性抑郁退伍军人,比较左侧前额叶rTMS(10 Hz,120%运动阈值,4000脉冲/次,最多30次)与假刺激的疗效。

要点

  • 活性rTMS与假刺激在难治性抑郁退伍军人中缓解率无显著差异。
  • 总体39.0%参与者达到抑郁症状缓解(HAMD≤10)。
  • 结果可能反映密切临床监测和药物管理对难治人群的重要性。

核心结论

  • 活性rTMS与假刺激在退伍军人难治性重性抑郁的缓解率上无显著差异。

研究设计与样本

  • 双盲假对照随机临床试验,2012年9月1日至2016年12月31日在9个退伍军人事务医疗中心进行,共164名难治性抑郁退伍军人参与。

主要发现

  • 164名参与者平均年龄55.2岁(SD 12.4),132名(80.5%)为男性,126名(76.8%)为白种人。
  • 81名随机接受活性rTMS,83名接受假刺激。
  • 急性治疗结束时活性组33/81(40.7%)达到缓解,假组31/83(37.4%)达到缓解。
  • 总体64/164(39.0%)参与者达到缓解。

关键数值与推荐

  • 活性rTMS参数:左侧前额叶,10 Hz,120%运动阈值,4000脉冲/次,最多30次治疗。
  • 主要结局缓解定义为汉密尔顿抑郁评定量表评分≤10。

临床怎么用

  • 对于难治性抑郁退伍军人,rTMS未显示优于假刺激的缓解率,临床决策需结合密切监测和药物管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment-resistant major depression (TRMD) in veterans is a major clinical challenge given the high risk for suicidality in these patients. Repetitive transcranial magnetic stimulation (rTMS) offers the potential for a novel treatment modality for these veterans. OBJECTIVE: To determine the efficacy of rTMS in the treatment of TRMD in veterans. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, sham-controlled randomized clinical trial was conducted from September 1, 2012, to December 31, 2016, in 9 Veterans Affairs medical centers. A total of 164 veterans with TRD participated. INTERVENTIONS: Participants were randomized to either left prefrontal rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session) or to sham (control) rTMS treatment for up to 30 treatment sessions. MAIN OUTCOMES AND MEASURES: The primary dependent measure of the intention-to-treat analysis was remission rate (Hamilton Rating Scale for Depression score ≤10, indicating that depression is in remission and not a clinically significant burden), and secondary analyses were conducted on other indices of posttraumatic stress disorder, depression, hopelessness, suicidality, and quality of life. RESULTS: The 164 participants had a mean (SD) age of 55.2 (12.4) years, 132 (80.5%) were men, and 126 (76.8%) were of white race. Of these, 81 were randomized to receive active rTMS and 83 to receive sham. For the primary analysis of remission, there was no significant effect of treatment (odds ratio, 1.16; 95% CI, 0.59-2.26; P = .67). At the end of the acute treatment phase, 33 of 81 (40.7%) of those in the active treatment group achieved remission of depressive symptoms compared with 31 of 83 (37.4%) of those in the sham treatment group. Overall, 64 of 164 (39.0%) of the participants achieved remission. CONCLUSIONS AND RELEVANCE: A total of 39.0% of the veterans who participated in this trial experienced clinically significant improvement resulting in remission of depressive symptoms; however, there was no evidence of difference in remission rates between the active and sham treatments. These findings may reflect the importance of close clinical surveillance, rigorous monitoring of concomitant medication, and regular interaction with clinic staff in bringing about significant improvement in this treatment-resistant population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01191333.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yesavage JA, Fairchild JK, Mi Z, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29955803. doi:10.1001/jamapsychiatry.2018.1483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。